DDInter856 DDInter471
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa). It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients. Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and prevention of post-operative deep venous thrombosis (DVT). While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer. The use of Orgaran™ was discontinued in the United States however it is available in several other countries including European countries and Japan. Danaparoid sodium is the common salt form in therapeutic preparations and is typically administered subcutaneously.
Danaparoid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Danaparoid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amiloride
Danaparoid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Protein C
Danaparoid {u} may lead to a major life threatening interaction when taken with {v} Desirudin
Danaparoid {u} may lead to a major life threatening interaction when taken with {v} Ibritumomab tiuxetan
Danaparoid may cause a minor interaction that can limit clinical effects when taken with Chamomile
Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Protein C
Danaparoid may lead to a major life threatening interaction when taken with Desirudin
Danaparoid may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan